Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
Correspondence: T. M. Carlos, MD, Division of Hematology/Oncology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213-2582. E-mail: Timothy.Carlos{at}med.va.gov
Biopsies of tumors responding to interleukin 2 (IL-2) based immunotherapy have been reported to show a leukocytic infiltration. Clinical responses to IL-2-based immunotherapy, however, are limited, suggesting a failure of leukocyte localization at tumor sites. Leukocyte infiltration at inflammatory sites requires local activation of leukocytes and endothelial cells in a coordinated and defined temporal sequence. There is evidence supporting the theory that infiltration of leukocytes at tumor sites is suboptimal due to a failure of coordination of these localizing events. In this review, factors involved in leukocyte recruitment at sites of inflammation and the coordination of these factors in a successful model of inflammation, i.e., wound healing, are discussed. This example is contrasted with events at tumor sites where alterations in expression of cell adhesion molecules or in the production of activating agents may be present. Additionally, the systemic administration of an activating cytokine such as IL-2 may fail to duplicate events that normally occur within a local environment. These observations may facilitate the design of future immunotherapy trials.
Key Words: adhesion • immunotherapy • cytokine • chemokine
This article has been cited by other articles:
 |
|
 |
|
  M. Terabe, E. Ambrosino, S. Takaku, J. J. O'Konek, D. Venzon, S. Lonning, J. M. McPherson, and J. A. Berzofsky Synergistic Enhancement of CD8+ T Cell-Mediated Tumor Vaccine Efficacy by an Anti-Transforming Growth Factor-{beta} Monoclonal Antibody Clin. Cancer Res., November 1, 2009; 15(21): 6560 - 6569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kim, G. Buchlis, Z. G. Fridlender, J. Sun, V. Kapoor, G. Cheng, A. Haas, H. K. Cheung, X. Zhang, M. Corbley, et al. Systemic Blockade of Transforming Growth Factor-{beta} Signaling Augments the Efficacy of Immunogene Therapy Cancer Res., December 15, 2008; 68(24): 10247 - 10256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matsumura, B. Wang, N. Kawashima, S. Braunstein, M. Badura, T. O. Cameron, J. S. Babb, R. J. Schneider, S. C. Formenti, M. L. Dustin, et al. Radiation-Induced CXCL16 Release by Breast Cancer Cells Attracts Effector T Cells J. Immunol., September 1, 2008; 181(5): 3099 - 3107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Lugade, E. W. Sorensen, S. A. Gerber, J. P. Moran, J. G. Frelinger, and E. M. Lord Radiation-Induced IFN-{gamma} Production within the Tumor Microenvironment Influences Antitumor Immunity J. Immunol., March 1, 2008; 180(5): 3132 - 3139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zheng and M. Martins-Green Molecular mechanisms of thrombin-induced interleukin-8 (IL-8/CXCL8) expression in THP-1-derived and primary human macrophages J. Leukoc. Biol., September 1, 2007; 82(3): 619 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. M. Dirkx, M. G. A. oude Egbrink, J. Wagstaff, and A. W. Griffioen Monocyte/macrophage infiltration in tumors: modulators of angiogenesis J. Leukoc. Biol., December 1, 2006; 80(6): 1183 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Janetopoulos, L. Ma, P. N. Devreotes, and P. A. Iglesias Chemoattractant-induced phosphatidylinositol 3,4,5-trisphosphate accumulation is spatially amplified and adapts, independent of the actin cytoskeleton PNAS, June 15, 2004; 101(24): 8951 - 8956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Devreotes and C. Janetopoulos Eukaryotic Chemotaxis: Distinctions between Directional Sensing and Polarization J. Biol. Chem., May 30, 2003; 278(23): 20445 - 20448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. E. Huang, M. Iijima, C. A. Parent, S. Funamoto, R. A. Firtel, and P. Devreotes Receptor-mediated Regulation of PI3Ks Confines PI(3,4,5)P3 to the Leading Edge of Chemotaxing Cells Mol. Biol. Cell, May 1, 2003; 14(5): 1913 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Duguay, F. Mercier, J. Stagg, D. Martineau, J. Bramson, M. Servant, R. Lin, J. Galipeau, and J. Hiscott In Vivo Interferon Regulatory Factor 3 Tumor Suppressor Activity in B16 Melanoma Tumors Cancer Res., September 15, 2002; 62(18): 5148 - 5152. [Abstract] [Full Text] [PDF]
|
|
